Summary#
This bill would bar a single company from owning both a pharmacy and either an insurance company or a pharmacy benefit manager (PBM). Its stated goal is to stop conflicts of interest that the bill says arise when PBMs or insurers own pharmacies, and to restore competition in prescription drug markets.
- Main change: Companies that both own or control a pharmacy and own or control an insurer or PBM must divest the pharmacy within one year.
- Enforcement: The Federal Trade Commission (FTC) and the Justice Department’s Antitrust Division have authority to enforce the rule. They must issue divestment milestones and can impose penalties for missed milestones.
- Penalties: For noncompliance with milestones, 10% of a firm’s profits would be placed into escrow monthly until divestiture or forfeited to an FTC-created fund if the divestiture never happens. Courts can order disgorgement (return) of pharmacy revenue earned during a violation into that fund.
- Private and state lawsuits: Individuals, state attorneys general, the HHS Inspector General, the FTC, and DOJ can bring civil suits. Private plaintiffs who win may receive treble (triple) damages plus attorney fees.
- Definitions and scope: “Pharmacy” covers many types (retail, mail-order, specialty, hospital, long-term care, etc.). “PBM” is broadly defined to cover entities that negotiate drug prices, run pharmacy networks, process claims, manage utilization, and similar services.
- Rulemaking and reports: The FTC must make rules to implement the law and the FTC and DOJ must send quarterly compliance reports to Congress.
What it means for you#
- Large integrated health companies and PBMs: If a company owns both a pharmacy and an insurer or PBM, it must sell or otherwise divest the pharmacy within one year. The company will face FTC/DOJ oversight and possible financial penalties if it misses divestment milestones.
- Pharmacies owned by insurers or PBMs: These pharmacies will likely be sold to new owners. The divestiture could change contracts, staffing, or locations depending on buyers.
- Independent and unaffiliated pharmacies: The bill is intended to reduce what the bill calls “self-preferencing” by integrated firms. This could increase competition for pharmacy business, though the bill does not guarantee specific outcomes.
- Patients and plan enrollees: The bill aims to reduce conflicts that could raise prescription drug costs. How much prices or coverage change is not specified.
- Health plans and employers: PBMs and insurers may change how they form pharmacy networks and negotiate prices if vertical ownership is eliminated.
- State attorneys general and private individuals: They may sue to enforce the law and can seek treble damages for harms alleged under the act.
- FTC and DOJ: Both agencies must review divestitures, may block future transactions that recreate the same conflicts, and must report quarterly to Congress.
Expenses#
No publicly available information.
- The bill requires the FTC to issue rules and both FTC and DOJ to review divestitures and send quarterly reports. This could increase agency workload and administrative costs, but no cost estimate is provided.
- The escrow penalty mechanism transfers 10% of a firm’s profits monthly for noncompliance; disgorged pharmacy revenue is deposited into an FTC fund for use in affected communities. The bill does not state how much money this will raise.
- Compliance costs for affected companies could include legal fees, transaction costs for divestitures, and possible litigation from private suits. These costs are not estimated in the bill text.
Proponents' View#
- The bill appears intended to remove conflicts of interest when PBMs or insurers also own pharmacies.
- A possible argument for the bill is that forced structural separation would prevent companies from steering patients to affiliated pharmacies and so restore fair competition among pharmacies.
- The bill could be seen as protecting independent pharmacies and consumers from contract pressure and potential closures caused by integrated competitors.
- It would give federal agencies, state attorneys general, and private parties clear tools to enforce separation and to block future deals that recreate the same conflicts.
Opponents' View#
- One concern is that the one-year divestiture deadline may be tight. Rapid forced sales could disrupt pharmacy services or reduce buyers for some locations, especially in rural or underserved areas.
- The bill leaves several practical details unclear, such as how “profits” are calculated for the 10% escrow penalty and how to value assets during trustee-run sales. This could produce litigation over measurement and process.
- The broad definitions of “PBM” and “pharmacy,” and the statute’s reach into many business arrangements, may create uncertainty for companies about whether they must divest.
- Allowing treble damages and broad private suits could increase litigation costs for firms and lead to more lawsuits.
- The bill requires FTC rulemaking and additional agency review, which could delay some transactions while increasing administrative burden; the text does not include specific budget or staffing resources to meet those demands.